Roche and Lucerne Festival renew partnership and launch new project for young composers

RocheRoche and the Lucerne Festival are renewing their partnership in the Roche Commissions cultural programme. Since the programme was launched in 2003 Roche has commissioned an orchestral work from a renowned composer. Since 2006 the programme has taken place in a two-year cycle.

In future, the Lucerne Festival will be the exclusive partner of Roche Commissions. From 2003 to 2012, Roche Commissions had been run by Roche and the three cultural institutions Lucerne Festival, Carnegie Hall and the Cleveland Orchestra. As in the past, a new work will be premiered every two years at the Lucerne Festival. Under the renewed partnership Roche will be the Resident Sponsor of the Lucerne Festival in Summer and a Resident Partner of the Lucerne Festival Academy from 2013 onwards.

The sixth Roche Commissions work, Matthias Pintscher's Chute d'Étoiles for two trumpets and orchestra, will premiere at the KKL (Culture and Convention Centre Lucerne) on Saturday, 25 August at 6.30 p.m. The Cleveland Orchestra will be performing under the baton of Franz Welser-Möst. Matthias Pintscher was born in 1971 in Marl, North Rhine-Westphalia, and currently resides in New York. Hans Werner Henze has been a champion of his music, as has Peter Eötvös, with whom Pintscher took a seminar in composition and who also taught him conducting. Matthias Pintscher has emerged with unusual speed to become recognized as one of the most successful composers of the generation. He was composer-in-residence at Lucerne Festival in 2006.

South Korean composer Unsuk Chin has been chosen to compose the seventh Roche Commissions work. Her composition for soprano and orchestra will be premiered at the 2014 Lucerne Festival in Summer by Barbara Hannigan and the Lucerne Festival Academy Orchestra, conducted by Sir Simon Rattle.

Unsuk Chin is one of the world's most sought-after composers. Now resident in Berlin, she studied composition first in her native city of Seoul, then from 1985 until 1988 with György Ligeti in Hamburg. The breakthrough came in 1985, when she was awarded First Prize in the Gaudeamus competition in Amsterdam. Unsuk Chin's musical idiom is modern but non-doctrinaire, lyrical and powerfully expressive. Her works have been performed by some of the world's most renowned orchestras and conductors, including the Berlin Philharmonic, the Chicago Symphony Orchestra, the City of Birmingham Symphony Orchestra, the Ensemble Modern, Esa-Pekka Salonen, Gustavo Dudamel and Kent Nagano. She has been composer in residence with the Deutsche Symphonie-Orchester in Berlin, Suntory Hall in Tokyo, and the Philharmonie Essen.

A further expression of the partnership between Roche and the Lucerne Festival is the launch of Roche Young Commissions. Every two years, alternating with the existing Roche Commissions programme, two young composers will be commissioned to write orchestral works which will then premiere at the Lucerne Festival, for the first time in 2015. The Roche Young Commissions awardees will have two years to complete their compositions, working closely with two young conductors and under the supervision of Pierre Boulez.

Franz Humer, Chairman of Roche: "We look back on many years of fruitful co-operation with the Lucerne Festival and are very pleased to have renewed this partnership for Roche Commissions and that we can continue developing it."

"It's marvellous," says Michael Haefliger, Director of the Lucerne Festival, "that in the world of business there are companies like Roche that are committed to promoting modern music and supporting the development of outstanding young talent. The innovative new collaboration between Roche and the Lucerne Festival Academy is a significant milestone in the history of our Festival."

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...